Fisher Asset Management LLC Has $1.29 Million Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Posted by on Apr 29th, 2023

Fisher Asset Management LLC lowered its position in Celldex Therapeutics, Inc. (NASDAQ:CLDX – Get Rating) by 14.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 29,017 shares of the biopharmaceutical company’s stock after selling 4,876 shares during the quarter. Fisher Asset Management LLC owned approximately 0.06% of Celldex Therapeutics worth $1,293,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in CLDX. JPMorgan Chase & Co. lifted its stake in Celldex Therapeutics by 365.0% in the first quarter. JPMorgan Chase & Co. now owns 34,888 shares of the biopharmaceutical company’s stock valued at $1,189,000 after acquiring an additional 48,054 shares during the last quarter. HighTower Advisors LLC acquired a new stake in shares of Celldex Therapeutics during the 1st quarter worth about $350,000. MetLife Investment Management LLC lifted its stake in shares of Celldex Therapeutics by 57.0% during the 1st quarter. MetLife Investment Management LLC now owns 25,208 shares of the biopharmaceutical company’s stock worth $859,000 after buying an additional 9,152 shares during the last quarter. Rhumbline Advisers lifted its stake in shares of Celldex Therapeutics by 4.8% during the 1st quarter. Rhumbline Advisers now owns 52,219 shares of the biopharmaceutical company’s stock worth $1,779,000 after buying an additional 2,396 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its stake in shares of Celldex Therapeutics by 31.8% during the 1st quarter. Dimensional Fund Advisors LP now owns 592,358 shares of the biopharmaceutical company’s stock worth $20,176,000 after buying an additional 142,761 shares during the last quarter.

Celldex Therapeutics Trading Down 0.9 %

Shares of Celldex Therapeutics stock opened at $31.44 on Friday. Celldex Therapeutics, Inc. has a twelve month low of $19.85 and a twelve month high of $48.40. The company has a current ratio of 17.07, a quick ratio of 17.07 and a debt-to-equity ratio of 0.01. The company has a 50-day simple moving average of $38.04 and a two-hundred day simple moving average of $39.11.

Celldex Therapeutics (NASDAQ:CLDX – Get Rating) last issued its quarterly earnings data on Tuesday, February 28th. The biopharmaceutical company reported ($0.56) earnings per share for the quarter, topping the consensus estimate of ($0.59) by $0.03. Celldex Therapeutics had a negative net margin of 4,765.59% and a negative return on equity of 28.90%. The business had revenue of $1.61 million during the quarter, compared to analysts’ expectations of $0.16 million. Equities research analysts predict that Celldex Therapeutics, Inc. will post -2.58 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the stock. HC Wainwright restated a “buy” rating and set a $73.00 target price on shares of Celldex Therapeutics in a research note on Wednesday, March 1st. StockNews.com assumed coverage on shares of Celldex Therapeutics in a research note on Thursday, March 16th. They set a “sell” rating for the company.

Celldex Therapeutics Company Profile

(Get Rating)

Celldex Therapeutics, Inc engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379.

Recommended Stories

Institutional Ownership by Quarter for Celldex Therapeutics (NASDAQ:CLDX)

Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.